Clinical validity of increased cortical uptake of [
Alzheimer’s disease
Biomarker-based diagnosis
PET
Strategic roadmap
[18F]flortaucipir
Journal
European journal of nuclear medicine and molecular imaging
ISSN: 1619-7089
Titre abrégé: Eur J Nucl Med Mol Imaging
Pays: Germany
ID NLM: 101140988
Informations de publication
Date de publication:
07 2021
07 2021
Historique:
received:
05
09
2020
accepted:
15
11
2020
pubmed:
7
2
2021
medline:
29
6
2021
entrez:
6
2
2021
Statut:
ppublish
Résumé
In 2017, the Geneva Alzheimer's disease (AD) Biomarker Roadmap initiative adapted the framework of the systematic validation of oncological diagnostic biomarkers to AD biomarkers, with the aim to accelerate their development and implementation in clinical practice. With this work, we assess the maturity of [ The level of maturity of [ The main aims of phases 1 (rationale for use) and 2 (discriminative ability) have been achieved. [ Current literature provides partial evidence for clinical utility of [
Identifiants
pubmed: 33547556
doi: 10.1007/s00259-020-05118-w
pii: 10.1007/s00259-020-05118-w
pmc: PMC8175307
doi:
Substances chimiques
Biomarkers
0
Carbolines
0
tau Proteins
0
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole
J09QS3Z3WB
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
2097-2109Références
Ashton N, Leuzy A, Karikari TK, et al. The validation status of blood biomarkers of amyloid and phospho-tau assessed with the 5- phase development framework for AD biomarkers. 2020.
Baek M, Cho H, Lee H, et al. Temporal trajectories of in vivo tau and amyloid-β accumulation in Alzheimer’s disease. Eur J Nucl Med Mol Imaging. 2020;47:2879–86.
Baker SL, Lockhart SN, Price JC, He M, Huesman RH, Schonhaut D, et al. Reference tissue-based kinetic evaluation of 18F-AV-1451 for tau imaging. J Nucl Med. 2017;58(2):332–8.
pubmed: 27587706
pmcid: 5288744
Barret O, Alagille D, Sanabria S, Comley RA, Weimer RM, Borroni E, et al. Kinetic modeling of the tau PET tracer (18)F-AV-1451 in human healthy volunteers and Alzheimer disease subjects. J Nucl Med. 2017;58(7):1124–31.
pubmed: 27908967
Bennett DA, Wilson RS, Schneider JA, Evans DA, Beckett LA, Aggarwal NT, et al. Natural history of mild cognitive impairment in older persons. Neurology. 2002;59(2):198–205.
pubmed: 12136057
Bischof GN, Jessen F, Fliessbach K, Dronse J, Hammes J, Neumaier B, et al. Impact of tau and amyloid burden on glucose metabolism in Alzheimer’s disease. Ann Clin Transl Neurol. 2016;3(12):934–9.
pubmed: 28097205
pmcid: 5224823
Bishof G, Dodich A, Boccardi M, et al. Clinical validity of increased cortical uptake of second-generation Tau PET tracers as a biomarker for Alzheimer’s disease in the context of a structured 5-phase development framework. 2020
Boccardi M, Dodich A, Albanese E, Gayet-Ageron A, Festari C, Ramusino M, et al. The strategic biomarker roadmap for the validation of Alzheimer’s diagnostic biomarkers: methodological update. EJNMMI. https://doi.org/10.1007/s00259-020-05120-2 .
Boccardi M, Festari C, Altomare D, Gandolfo F, Orini S, Nobili F, et al. Assessing FDG-PET diagnostic accuracy studies to develop recommendations for clinical use in dementia. Eur J Nucl Med Mol Imaging. 2018;45(9):1470–86.
pubmed: 29713763
Boccardi M, Gallo V, Yasui Y, Vineis P, Padovani A, Mosimann U, et al. The biomarker-based diagnosis of Alzheimer’s disease. 2-lessons from oncology. Neurobiol Aging. 2017;52:141–52.
pubmed: 28317645
Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol. 1991;82:239–59.
pubmed: 1759558
Braak H, Braak E. Frequency of stages of Alzheimer-related lesions in different age categories. Neurobiol Aging. 1997;18(4):351–7.
pubmed: 9330961
Buckley RF, Mormino EC, Rabin JS, Hohman TJ, Landau S, Hanseeuw BJ, et al. Sex differences in the association of global amyloid and regional tau deposition measured by positron emission tomography in clinically normal older adults. JAMA Neurol. 2019;76(5):542–51.
pubmed: 30715078
pmcid: 6515599
Cerami C, Dubois B, Boccardi M, Monsch AU, Demonet JF, Cappa SF, et al. Clinical validity of delayed recall tests as a gateway biomarker for Alzheimer’s disease in the context of a structured 5-phase development framework. Neurobiol Aging. 2017;52:153–66.
pubmed: 28317646
Chien DT, Bahri S, Szardenings AK, Walsh JC, Mu F, Su M-Y, et al. Early clinical PET imaging results with the novel PHF-tau radioligand [F-18]-T807. J Alzheimers Dis : JAD. 2013;34:457–68.
pubmed: 23234879
Chiotis K, Saint-Aubert L, Boccardi M, Gietl A, Picco A, Varrone A, et al. Clinical validity of increased cortical uptake of amyloid ligands on PET as a biomarker for Alzheimer’s disease in the context of a structured 5-phase development framework. Neurobiol Aging. 2017;52:214–27.
pubmed: 28317650
Chiotis K, Dodich A, Boccardi M, et al. Clinical validity of increased cortical uptake of tau ligands of the THK family and 11C-PBB3 on PET as biomarkers for Alzheimer’s disease in the context of a structured 5-phase development framework. 2020.
Cho H, Choi JY, Hwang MS, Lee JH, Kim YJ, Lee HM, et al. Tau PET in Alzheimer disease and mild cognitive impairment. Neurology. 2016;87(4):375–83.
pubmed: 27358341
Cho H, Choi JY, Lee HS, Lee JH, Ryu YH, Lee MS, Jack CR Jr, Lyoo CH. Progressive Tau Accumulation in Alzheimer Disease: 2-Year Follow-up Study. J Nucl Med. 2019;60(11):1611–21.
Cho H, Choi JY, Lee SH, Lee JH, Choi YC, Ryu YH, et al. Excessive tau accumulation in the parieto-occipital cortex characterizes early-onset Alzheimer’s disease. Neurobiol Aging. 2017;53:103–11.
pubmed: 28254589
Crary JF, Trojanowski JQ, Schneider JA, Abisambra JF, Abner EL, Alafuzoff I, et al. Primary age-related tauopathy (PART): a common pathology associated with human aging. Acta Neuropathol. 2014;128(6):755–66.
pubmed: 25348064
pmcid: 4257842
Dani M, Wood M, Mizoguchi R, Fan Z, Edginton T, Hinz R, et al. Tau aggregation correlates with amyloid deposition in both mild cognitive impairment and Alzheimer’s disease subjects. J Alzheimers Dis. 2019;70(2):455–65.
pubmed: 31256120
Das SR, Xie L, Wisse LEM, Ittyerah R, Tustison NJ, Dickerson BC, et al. Longitudinal and cross-sectional structural magnetic resonance imaging correlates of AV-1451 uptake. Neurobiol Aging. 2018;66:49–58.
pubmed: 29518752
pmcid: 5924615
Devous MD Sr, Joshi AD, Navitsky M, Southekal S, Pontecorvo MJ, Shen H, et al. Test-retest reproducibility for the tau PET imaging agent flortaucipir F 18. J Nucl Med. 2018;59(6):937–43.
pubmed: 29284675
Dronse J, Fliessbach K, Bischof GN, von Reutern B, Faber J, Hammes J, et al. In vivo patterns of tau pathology, amyloid-beta burden, and neuronal dysfunction in clinical variants of Alzheimer’s disease. J Alzheimers Dis. 2017;55(2):465–71.
pubmed: 27802224
Dubois B, Feldman HH, Jacova C, Hampel H, Molinuevo JL, Blennow K, et al. Advancing research diagnostic criteria for Alzheimer’s disease: the IWG-2 criteria. Lancet Neurol. 2014;13:614–29.
pubmed: 24849862
FDA. FDA approves first drug to image tau pathology in patients being evaluated for Alzheimer’s disease. https://www.fda.gov/news-events/press-announcements/fda-approves-first-drug-image-tau-pathology-patients-being-evaluated-alzheimers-disease . Accessed 1 June 2020
Firouzian A, Whittington A, Searle GE, Koychev I, Zamboni G, Lovestone S, Gunn RN. Deep and Frequent Phenotyping study team. Imaging Aβ and tau in early stage Alzheimer’s disease with [18F]AV45 and [18F]AV1451. EJNMMI Res. 2018;8(1):19.
Fleisher AS, Pontecorvo MJ, Devous MD Sr, Lu M, Arora AK, Truocchio SP, et al. Positron emission tomography imaging with [18F]flortaucipir and postmortem assessment of Alzheimer disease neuropathologic changes. JAMA Neurol. 2020;77(7):829–39.
Frisoni GB, Boccardi M, Barkhof F, Blennow K, Cappa S, Chiotis K, et al. Strategic roadmap for an early diagnosis of Alzheimer’s disease based on biomarkers. Lancet Neurol. 2017;16(8):661–76.
pubmed: 28721928
Gao M, Wang M, Zheng QH. Fully automated synthesis of [(18)F]T807, a PET tau tracer for Alzheimer’s disease. Bioorg Med Chem Lett. 2015;25(15):2953–7.
pubmed: 26048805
Garibotto V, Herholz K, Boccardi M, Picco A, Varrone A, Nordberg A, et al. Clinical validity of brain fluorodeoxyglucose positron emission tomography as a biomarker for Alzheimer’s disease in the context of a structured 5-phase development framework. Neurobiol Aging. 2017;52:183–95.
pubmed: 28317648
Ghisays V, Goradia DD, Protas H, Bauer RJ 3rd, Devadas V, Tariot PN, et al. Brain imaging measurements of fibrillar amyloid-beta burden, paired helical filament tau burden, and atrophy in cognitively unimpaired persons with two, one, and no copies of the APOE epsilon4 allele. Alzheimers Dement. 2020;16(4):598–609.
pubmed: 31831374
pmcid: 7187298
Golla SSV, Timmers T, Ossenkoppele R, Groot C, Verfaillie S, Scheltens P, et al. Quantification of tau load using [18F]AV1451 PET. Mol Imaging Biol. 2017;19(6):963–71.
pubmed: 28374171
pmcid: 5662681
Gordon BA, Friedrichsen K, Brier M, Blazey T, Su Y, Christensen J, et al. The relationship between cerebrospinal fluid markers of Alzheimer pathology and positron emission tomography tau imaging. Brain. 2016;139(Pt 8):2249–60.
pubmed: 27286736
pmcid: 4958902
Graff-Radford J, Arenaza-Urquijo EM, Knopman DS, Schwarz CG, Brown RD, Rabinstein AA, et al. White matter hyperintensities: relationship to amyloid and tau burden. Brain. 2019;142(8):2483–91.
pubmed: 31199475
pmcid: 6658846
Grundke-Iqbal I, Iqbal K, Tung YC, Quinlan M, Wisniewski HM, Binder LI. Abnormal phosphorylation of the microtubule-associated protein tau (tau) in Alzheimer cytoskeletal pathology. Proc Natl Acad Sci U S A. 1986;83:4913–7.
pubmed: 3088567
pmcid: 323854
Guyatt G, Oxman AD, Akl EA, Kunz R, Vist G, Brozek J, et al. GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables. J Clin Epidemiol. 2011;64(4):383–94.
Hahn A, Schain M, Erlandsson M, Sjolin P, James GM, Strandberg OT, et al. Modeling strategies for quantification of in vivo (18)F-AV-1451 binding in patients with tau pathology. J Nucl Med. 2017;58(4):623–31.
pubmed: 27765859
Hanseeuw BJ, Betensky RA, Jacobs HIL, Schultz AP, Sepulcre J, Becker JA, et al. Association of amyloid and tau with cognition in preclinical Alzheimer disease: a longitudinal study. JAMA Neurol. 2019;76(8):915–24.
Harrison TM, La Joie R, Maass A, Baker SL, Swinnerton K, Fenton L, et al. Longitudinal tau accumulation and atrophy in aging and Alzheimer disease. Ann Neurol. 2019;85(2):229–40.
pubmed: 30597624
pmcid: 6579738
Heurling K, Smith R, Strandberg OT, Schain M, Ohlsson T, Hansson O, et al. Regional times to equilibria and their impact on semi-quantification of [F-18]AV-1451 uptake. J Cereb Blood Flow Metab. 2019;39(11):2223–32.
pubmed: 30073880
Hoenig MC, Bischof GN, Hammes J, Faber J, Fliessbach K, van Eimeren T, et al. Tau pathology and cognitive reserve in Alzheimer’s disease. Neurobiol Aging. 2017;57:1–7.
pubmed: 28577411
Holt DP, Ravert HT, Dannals RF. Synthesis and quality control of [(18) F]T807 for tau PET imaging. J Label Compd Radiopharm. 2016;59(10):411–5.
Hyman BT, Phelps CH, Beach TG, Bigio EH, Cairns NJ, Carrillo MC, et al. National Institute on Aging-Alzheimer’s Association guidelines for the neuropathologic assessment of Alzheimer’s disease. Alzheimers Dement. 2012;8(1):1–13.
pubmed: 22265587
pmcid: 3266529
Iaccarino L, Tammewar G, Ayakta N, Baker SL, Bejanin A, Boxer AL, et al. Local and distant relationships between amyloid, tau and neurodegeneration in Alzheimer’s disease. Neuroimage Clin. 2018;17:452–64.
pubmed: 29159058
Jack CR Jr, Bennett DA, Blennow K, Carrillo MC, Dunn B, Haeberlein SB, et al. NIA-AA research framework: toward a biological definition of Alzheimer’s disease. Alzheimers Dement. 2018a;14(4):535–62.
pubmed: 29653606
pmcid: 5958625
Jack CR Jr, Lowe VJ, Senjem ML, Weigand SD, Kemp BJ, Shiung MM, et al. 11C PiB and structural MRI provide complementary information in imaging of Alzheimer’s disease and amnestic mild cognitive impairment. Brain. 2008;131(Pt 3):665–80.
pubmed: 18263627
pmcid: 2730157
Jack CR Jr, Wiste HJ, Schwarz CG, Lowe VJ, Senjem ML, Vemuri P, et al. Longitudinal tau PET in ageing and Alzheimer’s disease. Brain. 2018b;141(5):1517–28.
pubmed: 29538647
pmcid: 5917767
Jack CR Jr, Wiste HJ, Therneau TM, Weigand SD, Knopman DS, Mielke MM, et al. Associations of amyloid, tau, and neurodegeneration biomarker profiles with rates of memory decline among individuals without dementia. JAMA. 2019;321(23):2316–25.
pubmed: 31211344
pmcid: 6582267
Jack CR Jr, Wiste HJ, Weigand SD, Therneau TM, Lowe VJ, Knopman DS, et al. Defining imaging biomarker cut points for brain aging and Alzheimer’s disease. Alzheimers Dement. 2017;13(3):205–16.
pubmed: 27697430
Jack CR, Wiste HJ, Botha H, Weigand SD, Therneau TM, Knopman DS, et al. The bivariate distribution of amyloid-beta and tau: relationship with established neurocognitive clinical syndromes. Brain. 2019;142(10):3230–42.
pubmed: 31501889
pmcid: 6763736
Jacobs HIL, Hedden T, Schultz AP, Sepulcre J, Perea RD, Amariglio RE, et al. Structural tract alterations predict downstream tau accumulation in amyloid-positive older individuals. Nat Neurosci. 2018;21(3):424–31.
pubmed: 29403032
pmcid: 5857215
Janelidze S, Mattsson N, Palmqvist S, Smith R, Beach TG, Serrano GE, et al. Plasma P-tau181 in Alzheimer’s disease: relationship to other biomarkers, differential diagnosis, neuropathology and longitudinal progression to Alzheimer’s dementia. Nat Med. 2020a;26(3):379–86.
pubmed: 32123385
Janelidze S, Stomrud E, Smith R, Palmqvist S, Mattsson N, Airey DC, et al. Cerebrospinal fluid p-tau217 performs better than p-tau181 as a biomarker of Alzheimer’s disease. Nat Commun. 2020b;11(1):1683.
pubmed: 32246036
pmcid: 7125218
Johnson KA, Schultz A, Betensky RA, Becker JA, Sepulcre J, Rentz D, et al. Tau positron emission tomographic imaging in aging and early Alzheimer disease. Ann Neurol. 2016;79(1):110–9.
pubmed: 26505746
Josephs KA, Tosakulwong N, Graff-Radford J, Weigand SD, Buciuc M, Machulda MM, et al. MRI and flortaucipir relationships in Alzheimer’s phenotypes are heterogeneous. Ann Clin Transl Neurol. 2020;7(5):707–21.
Kobe T, Gonneaud J, Pichet Binette A, Meyer PF, McSweeney M, Rosa-Neto P, et al. Association of vascular risk factors with beta-amyloid peptide and tau burdens in cognitively unimpaired individuals and its interaction with vascular medication use. JAMA Netw Open. 2020;3(2):e1920780.
pubmed: 32031648
Koychev I, Gunn RN, Firouzian A, Lawson J, Zamboni G, Ridha B, et al. PET tau and amyloid-beta burden in mild Alzheimer’s disease: divergent relationship with age, cognition, and cerebrospinal fluid biomarkers. J Alzheimers Dis. 2017;60(1):283–93.
pubmed: 28800330
pmcid: 5612013
La Joie R, Bejanin A, Fagan AM, Ayakta N, Baker SL, Bourakova V, et al. Associations between [(18)F]AV1451 tau PET and CSF measures of tau pathology in a clinical sample. Neurology. 2018;90(4):e282–90.
pubmed: 29282337
pmcid: 5798657
La Joie R, Visani AV, Baker SL, Brown JA, Bourakova V, Cha J, et al. Prospective longitudinal atrophy in Alzheimer’s disease correlates with the intensity and topography of baseline tau-PET. Sci Transl Med. 2020;12(524):eaau5732.
Leal SL, Lockhart SN, Maass A, Bell RK, Jagust WJ. Subthreshold amyloid predicts tau deposition in aging. J Neurosci. 2018;38(19):4482–9.
pubmed: 29686045
pmcid: 5943976
Lee CM, Jacobs HIL, Marquie M, Becker JA, Andrea NV, Jin DS, et al. 18F-Flortaucipir binding in choroid plexus: related to race and hippocampus signal. J Alzheimers Dis. 2018;62(4):1691–702.
pubmed: 29614677
pmcid: 5957532
Leuzy A, Ashton N, Dodich A, et al. Update on the clinical validity of cerebrospinal fluid amyloid, tau, and phospho-tau as biomarkers for Alzheimer’s disease in the context of a structured 5-phase development framework. 2020;EJNM-S-20-02071.
Liu M, Paranjpe MD, Zhou X, Duy PQ, Goyal MS, Benzinger TLS, et al. Sex modulates the ApoE epsilon4 effect on brain tau deposition measured by (18)F-AV-1451 PET in individuals with mild cognitive impairment. Theranostics. 2019;9(17):4959–70.
pubmed: 31410194
pmcid: 6691387
Lockhart SN, Scholl M, Baker SL, Ayakta N, Swinnerton KN, Bell RK, et al. Amyloid and tau PET demonstrate region-specific associations in normal older people. Neuroimage. 2017;150:191–9.
pubmed: 28232190
pmcid: 5391247
Lowe VJ, Bruinsma TJ, Min HK, Lundt ES, Fang P, Senjem ML, et al. Elevated medial temporal lobe and pervasive brain tau-PET signal in normal participants. Alzheimers Dement (Amst). 2018a;10:210–6.
Lowe VJ, Curran G, Fang P, Liesinger AM, Josephs KA, Parisi JE, et al. An autoradiographic evaluation of AV-1451 tau PET in dementia. Acta Neuropathol Commun. 2016;4(1):58.
pubmed: 27296779
pmcid: 4906968
Lowe VJ, Lundt ES, Albertson SM, Min HK, Fang P, Przybelski SA, et al. Tau-positron emission tomography correlates with neuropathology findings. Alzheimers Dement. 2020;16(3):561–71.
pubmed: 31784374
pmcid: 7067654
Lowe VJ, Wiste HJ, Senjem ML, Weigand SD, Therneau TM, Boeve BF, et al. Widespread brain tau and its association with ageing, Braak stage and Alzheimer’s dementia. Brain. 2018b;141(1):271–87.
pubmed: 29228201
Maass A, Landau S, Baker SL, Horng A, Lockhart SN, La Joie R, et al. Comparison of multiple tau-PET measures as biomarkers in aging and Alzheimer’s disease. Neuroimage. 2017;157:448–63.
pubmed: 28587897
pmcid: 5814575
Maass A, Lockhart SN, Harrison TM, Bell RK, Mellinger T, Swinnerton K, et al. Entorhinal tau pathology, episodic memory decline, and neurodegeneration in aging. J Neurosci. 2018;38(3):530–43.
pubmed: 29192126
pmcid: 5777108
Mak E, Bethlehem RAI, Romero-Garcia R, Cervenka S, Rittman T, Gabel S, et al. In vivo coupling of tau pathology and cortical thinning in Alzheimer’s disease. Alzheimers Dement (Amst). 2018;10:678–87.
Marquie M, Normandin MD, Meltzer AC, Chong MST, Andrea NV, Anton-Fernandez A, et al. Pathological correlations of [F-18]-AV-1451 imaging in non-Alzheimer tauopathies. Ann Neurol. 2017;81(1):117–28.
pubmed: 27997036
pmcid: 5319193
Marquie M, Normandin MD, Vanderburg CR, Costantino I, Bien EA, Rycyna LG, et al. Validating novel tau PET tracer [F-18]-AV-1451 (T807) on postmortem brain tissue. Ann Neurol. 2015;78(5):787–800.
Mattsson-Carlgren N, Andersson E, Janelidze S, Ossenkoppele R, Insel P, Strandberg O, et al. A beta deposition is associated with increases in soluble and phosphorylated tau that precede a positive tau PET in Alzheimer’s disease. Sci Adv. 2020;6(16):eaaz2387
Mattsson N, Insel PS, Donohue M, Jogi J, Ossenkoppele R, Olsson T, et al. Predicting diagnosis and cognition with (18)F-AV-1451 tau PET and structural MRI in Alzheimer’s disease. Alzheimers Dement. 2019 Apr;15(4):570–80
Mattsson N, Lonneborg A, Boccardi M, Blennow K, Hansson O, B. Geneva Task Force for the Roadmap of Alzheimer's. Clinical validity of cerebrospinal fluid Abeta42, tau, and phospho-tau as biomarkers for Alzheimer’s disease in the context of a structured 5-phase development framework. Neurobiol Aging. 2017a;52:196–213.
pubmed: 28317649
Mattsson N, Ossenkoppele R, Smith R, Strandberg O, Ohlsson T, Jogi J, et al. Greater tau load and reduced cortical thickness in APOE epsilon4-negative Alzheimer’s disease: a cohort study. Alzheimers Res Ther. 2018a;10(1):77.
pubmed: 30086796
pmcid: 6081879
Mattsson N, Scholl M, Strandberg O, Smith R, Palmqvist S, Insel PS, et al. (18)F-AV-1451 and CSF T-tau and P-tau as biomarkers in Alzheimer’s disease. EMBO Mol Med. 2017b;9(9):1212–23.
pubmed: 28743782
pmcid: 5582410
Mattsson N, Smith R, Strandberg O, Palmqvist S, Scholl M, Insel PS, et al. Comparing (18)F-AV-1451 with CSF t-tau and p-tau for diagnosis of Alzheimer disease. Neurology. 2018b;90(5):e388–95.
pubmed: 29321235
pmcid: 5791788
McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer’s disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s disease. Neurology. 1984;34:939–44.
pubmed: 6610841
McSweeney M, Binette AP, Meyer PF, Gonneaud J, Bedetti C, Ozlen H, et al. Intermediate flortaucipir uptake is associated with Abeta-PET and CSF tau in asymptomatic adults. Neurology. 2020;94(11):e1190–200.
pubmed: 32015176
Meyer PF, Binette AP, Gonneaud J, Breitner JCS, Villeneuve S. Characterization of Alzheimer disease biomarker discrepancies using cerebrospinal fluid phosphorylated tau and AV1451 positron emission tomography. JAMA Neurol. 2020;77(4):508–16.
Mishra S, Gordon BA, Su Y, Christensen J, Friedrichsen K, Jackson K, et al. AV-1451 PET imaging of tau pathology in preclinical Alzheimer disease: defining a summary measure. Neuroimage. 2017;161:171–8.
pubmed: 28756238
pmcid: 5696044
Mossine AV, Brooks AF, Henderson BD, Hockley BG, Frey KA, Scott PJH. An updated radiosynthesis of [(18)F]AV1451 for tau PET imaging. EJNMMI Radiopharm Chem. 2017;2(1):7.
pubmed: 29503848
pmcid: 5824695
Okafor M, Nye JA, Shokouhi M, Shaw LM, Goldstein F, Hajjar I. 18F-flortaucipir PET associations with cerebrospinal fluid, cognition, and neuroimaging in mild cognitive impairment due to Alzheimer’s disease. J Alzheimers Dis. 2020;74(2):589–601.
pubmed: 32065800
Ossenkoppele R, Lyoo CH, Jester-Broms J, Sudre CH, Cho H, Ryu YH, et al. Assessment of demographic, genetic, and imaging variables associated with brain resilience and cognitive resilience to pathological tau in patients with Alzheimer disease. JAMA Neurol. 2020a;77(5):632–42.
pubmed: 32091549
Ossenkoppele R, Lyoo CH, Sudre CH, van Westen D, Cho H, Ryu YH, et al. Distinct tau PET patterns in atrophy-defined subtypes of Alzheimer’s disease. Alzheimers Dement. 2020b;16(2):335–44.
pubmed: 31672482
pmcid: 7012375
Ossenkoppele R, Rabinovici GD, Smith R, Cho H, Scholl M, Strandberg O, et al. Discriminative accuracy of [18F]flortaucipir positron emission tomography for Alzheimer disease vs other neurodegenerative disorders. JAMA. 2018;320(11):1151–62.
pubmed: 30326496
pmcid: 6233630
Ossenkoppele R, Schonhaut DR, Baker SL, James P, Neil O, Janabi M, et al. Tau, amyloid, and hypometabolism in a patient with posterior cortical atrophy. Ann Neurol. 2015;77(2):338–42.
Ossenkoppele R, Schonhaut DR, Scholl M, Lockhart SN, Ayakta N, Baker SL, et al. Tau PET patterns mirror clinical and neuroanatomical variability in Alzheimer’s disease. Brain. 2016;139(Pt 5):1551–67.
pubmed: 26962052
pmcid: 5006248
Ossenkoppele R, Smith R, Ohlsson T, Strandberg O, Mattsson N, Insel PS, et al. Associations between tau, Abeta, and cortical thickness with cognition in Alzheimer disease. Neurology. 2019;92(6):e601–12.
pubmed: 30626656
pmcid: 6382060
Pepe MS, Etzioni R, Feng Z, Potter JD, Thompson ML, Thornquist M, et al. Phases of biomarker development for early detection of cancer. J Natl Cancer Inst. 2001;93(14):1054–61.
pubmed: 11459866
Pereira JB, Harrison TM, La Joie R, Baker SL, Jagust WJ. Spatial patterns of tau deposition are associated with amyloid, ApoE, sex, and cognitive decline in older adults. Eur J Nucl Med Mol Imaging. 2020;47(9):2155–2164.
Pontecorvo MJ, Devous MD, Kennedy I, Navitsky M, Lu M, Galante N, et al. A multicentre longitudinal study of flortaucipir (18F) in normal ageing, mild cognitive impairment and Alzheimer’s disease dementia. Brain. 2019;142(6):1723–35.
pubmed: 31009046
pmcid: 6536847
Pontecorvo MJ, Devous MD Sr, Navitsky M, Lu M, Salloway S, Schaerf FW, et al. Relationships between flortaucipir PET tau binding and amyloid burden, clinical diagnosis, age and cognition. Brain. 2017;140(3):748–63.
pubmed: 28077397
pmcid: 5382945
Price JL, Morris JC. Tangles and plaques in nondemented aging and “preclinical” Alzheimer’s disease. Ann Neurol. 1999;45(3):358–68.
pubmed: 10072051
Rabin JS, Yang HS, Schultz AP, Hanseeuw BJ, Hedden T, Viswanathan A, et al. Vascular risk and beta-amyloid are synergistically associated with cortical tau. Ann Neurol. 2019;85(2):272–9.
pubmed: 30565287
pmcid: 6351182
Ramanan VK, Castillo AM, Knopman DS, Graff-Radford J, Lowe VJ, Petersen RC, et al. Association of apolipoprotein E varepsilon4, educational level, and sex with tau deposition and tau-mediated metabolic dysfunction in older adults. JAMA Netw Open. 2019;2(10):e1913909.
pubmed: 31642932
pmcid: 6820045
Rowe CC, Ellis KA, Rimajova M, Bourgeat P, Pike KE, Jones G, et al. Amyloid imaging results from the Australian imaging, biomarkers and lifestyle (AIBL) study of aging. Neurobiol Aging. 2010;31:1275–83.
pubmed: 20472326
Scholl M, Lockhart SN, Schonhaut DR, O'Neil JP, Janabi M, Ossenkoppele R, et al. PET imaging of tau deposition in the aging human brain. Neuron. 2016;89(5):971–82.
pubmed: 26938442
pmcid: 4779187
Scholl M, Ossenkoppele R, Strandberg O, Palmqvist S, F. S. Swedish Bio, Jogi J, et al. Distinct 18F-AV-1451 tau PET retention patterns in early- and late-onset Alzheimer’s disease. Brain. 2017;140(9):2286–94.
pubmed: 29050382
Schwarz AJ, Yu P, Miller BB, Shcherbinin S, Dickson J, Navitsky M, et al. Regional profiles of the candidate tau PET ligand 18F-AV-1451 recapitulate key features of Braak histopathological stages. Brain. 2016;139(Pt 5):1539–50.
pubmed: 26936940
Sepulcre J, Schultz AP, Sabuncu M, Gomez-Isla T, Chhatwal J, Becker A, et al. In vivo tau, amyloid, and gray matter profiles in the aging brain. J Neurosci. 2016;36(28):7364–74.
pubmed: 27413148
pmcid: 4945661
Shoup TM, Yokell DL, Rice PA, Jackson RN, Livni E, Johnson KA, et al. A concise radiosynthesis of the tau radiopharmaceutical, [(18) F]T807. J Label Compd Radiopharm. 2013;56(14):736–40.
Sintini I, Graff-Radford J, Senjem ML, Schwarz CG, Machulda MM, Martin PR, et al. Longitudinal neuroimaging biomarkers differ across Alzheimer’s disease phenotypes. Brain. 2020;143(7):2281–2294
Smith R, Puschmann A, Scholl M, Ohlsson T, van Swieten J, Honer M, et al. 18F-AV-1451 tau PET imaging correlates strongly with tau neuropathology in MAPT mutation carriers. Brain. 2016;139(Pt 9):2372–9.
pubmed: 27357347
pmcid: 4995360
Sonni I, Ratib O, Boccardi M, Picco A, Herholz K, Nobili F, et al. Clinical validity of presynaptic dopaminergic imaging with (123)I-ioflupane and noradrenergic imaging with (123)I-MIBG in the differential diagnosis between Alzheimer’s disease and dementia with Lewy bodies in the context of a structured 5-phase development framework. Neurobiol Aging. 2017;52:228–42.
pubmed: 28317651
Sperling RA, Mormino EC, Schultz AP, Betensky RA, Papp KV, Amariglio RE, et al. The impact of amyloid-beta and tau on prospective cognitive decline in older individuals. Ann Neurol. 2019;85(2):181–93.
pubmed: 30549303
pmcid: 6402593
Ten Kate M, Barkhof F, Boccardi M, Visser PJ, Jack CR Jr, Lovblad KO, et al. Clinical validity of medial temporal atrophy as a biomarker for Alzheimer’s disease in the context of a structured 5-phase development framework. Neurobiol Aging. 2017;52(167–182):e161.
Therriault J, Benedet AL, Pascoal TA, Mathotaarachchi S, Chamoun M, Savard M, et al. Association of apolipoprotein E epsilon4 with medial temporal tau independent of amyloid-beta. JAMA Neurol. 2020;77(4):470–9.
Thijssen EH, La Joie R, Wolf A, Strom A, Wang P, Iaccarino L, et al. Diagnostic value of plasma phosphorylated tau181 in Alzheimer’s disease and frontotemporal lobar degeneration. Nat Med. 2020;26(3):387–97.
pubmed: 32123386
pmcid: 7101073
Timmers T, Ossenkoppele R, Visser D, Tuncel T, Wolters EE, Verfaillie S, et al. Test-retest repeatability of [18F]Flortaucipir PET in Alzheimer’s disease and cognitively normal individuals. J Cereb Blood Flow Metab. 2020;40(12):2464–74.
Timmers T, Ossenkoppele R, Wolters EE, Verfaillie SCJ, Visser D, Golla SSV, et al. Associations between quantitative [(18)F]flortaucipir tau PET and atrophy across the Alzheimer’s disease spectrum. Alzheimers Res Ther. 2019b;11(1):60.
pubmed: 31272512
pmcid: 6610969
Tosun D, Landau S, Aisen PS, Petersen RC, Mintun M, Jagust W, et al. Association between tau deposition and antecedent amyloid-beta accumulation rates in normal and early symptomatic individuals. Brain. 2017;140(5):1499–512.
pubmed: 28334939
Villemagne VL, Doré V, Bourgeat P. The tau MeTeR composites for the generation of continuous and categorical measures of tau deposits in the brain. J Mol Med Ther. 2017;1(1):25–32.
Vogel JW, Mattsson N, Iturria-Medina Y, Strandberg OT, Scholl M, Dansereau C, et al. Data-driven approaches for tau-PET imaging biomarkers in Alzheimer’s disease. Hum Brain Mapp. 2019;40(2):638–51.
pubmed: 30368979
Wang L, Benzinger TL, Su Y, Christensen J, Friedrichsen K, Aldea P, et al. Evaluation of tau imaging in staging Alzheimer disease and revealing interactions between beta-amyloid and tauopathy. Jama Neurol. 2016;73(9):1070–7.
pubmed: 27454922
pmcid: 5237382
Weigand AJ, Bangen KJ, Thomas KR, Delano-Wood L, Gilbert PE, Brickman AM, et al. Is tau in the absence of amyloid on the Alzheimer’s continuum?: A study of discordant PET positivity. Brain Commun. 2020a;2(1):fcz046.
pubmed: 32051933
Weigand AJ, Thomas KR, Bangen KJ, Eglit GML, Delano-Wood L, Gilbert PE, et al. APOE interacts with tau PET to influence memory independently of amyloid PET in older adults without dementia. Alzheimers Dement. 2021 Jan;17(1):61–69.
Whitwell JL, Graff-Radford J, Tosakulwong N, Weigand SD, Machulda M, Senjem ML, et al. [(18) F]AV-1451 clustering of entorhinal and cortical uptake in Alzheimer’s disease. Ann Neurol. 2018a;83(2):248–57.
pubmed: 29323751
pmcid: 5821532
Whitwell JL, Graff-Radford J, Tosakulwong N, Weigand SD, Machulda MM, Senjem ML, et al. Imaging correlations of tau, amyloid, metabolism, and atrophy in typical and atypical Alzheimer’s disease. Alzheimers Dement. 2018b;14(8):1005–14.
pubmed: 29605222
pmcid: 6097955
Wolters EE, Ossenkoppele R, Verfaillie SCJ, Coomans EM, Timmers T, Visser D, et al. Regional [(18)F]flortaucipir PET is more closely associated with disease severity than CSF p-tau in Alzheimer’s disease. Eur J Nucl Med Mol Imaging. 2020;47(12):2866–2878.
Wooten DW, Guehl NJ, Verwer EE, Shoup TM, Yokell DL, Zubcevik N, et al. Pharmacokinetic evaluation of the tau PET radiotracer (18)F-T807 ((18)F-AV-1451) in human subjects. J Nucl Med. 2017;58(3):484–91.
pubmed: 27660144
pmcid: 5334185
Xia C-F, Arteaga J, Chen G, Gangadharmath U, Gomez LF, Kasi D, et al. [(18)F]T807, a novel tau positron emission tomography imaging agent for Alzheimer’s disease. Alzheimers Dement. 2013a;9:666–76.
pubmed: 23411393
Xia C, Makaretz SJ, Caso C, McGinnis S, Gomperts SN, Sepulcre J, et al. Association of in vivo [18F]AV-1451 tau PET imaging results with cortical atrophy and symptoms in typical and atypical Alzheimer disease. JAMA Neurol. 2017;74(4):427–436
Ziontz J, Bilgel M, Shafer AT, Moghekar A, Elkins W, Helphrey J, et al. Tau pathology in cognitively normal older adults. Alzheimers Dement (Amst). 2019;11:637–45.